CYTH Cyclo Therapeutics
- 1.300
- +0.090+7.44%
- 1.250
- -0.050-3.85%
Cyclo Therapeutics News
Cyclo Therapeutics | 10-K: Annual report
Cyclo Therapeutics | 8-K/A: Current report (Amendment)
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director STRATTAN CE RICK
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wong Vivien
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sieger Markus
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ostronic Francis Patrick
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Toig Randall M.
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SHANAHAN WILLIAM S
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director CONKLING WILLIAM
Cyclo Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)
Cyclo Therapeutics | 8-K: Current report
Cyclo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Cross Shawn
Cyclo Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Cross Shawn
Cyclo Therapeutics | 8-K: Current report
Cyclo Therapeutics | 8-K: Current report
Cyclo Therapeutics | 8-K: Current report
Cyclo Therapeutics | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Cyclo Therapeutics | 8-K: Current report
Cyclo Therapeutics | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
Cyclo Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
